Literature DB >> 10326588

Characterization of drug-resistant cell lines by comparative genomic hybridization.

K M Carlson1, A Gruber, E Liliemark, R Larsson, M Nordenskjöld.   

Abstract

The development of resistance to cytostatic agents is a serious obstacle to the success of cancer therapy and has been the focus of many research efforts. Traditionally, cell lines are selectively cultured in the presence of cytostatic agents and the biochemical and cytogenetic properties of the cell lines are then analyzed. In order to better understand the mechanisms by which drug resistance is mediated, we have analyzed three cell lines, each derived from the parent line K562, which are resistant to vincristine, mitoxantrone, or idarubicin, using comparative genomic hybridization (CGH). In each case, CGH successfully identified amplifications and/or deletions unique to the drug-resistant selected cell lines. Further characterization of the genetic regions identified in the CGH analysis could greatly contribute to our understanding of acquired drug resistance, and could potentially impact the clinical management of cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10326588     DOI: 10.1016/s0165-4608(98)00222-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.

Authors:  Michael A Morgan; Fredrick O Onono; H Peter Spielmann; Thangaiah Subramanian; Michaela Scherr; Letizia Venturini; Iris Dallmann; Arnold Ganser; Christoph W M Reuter
Journal:  J Mol Med (Berl)       Date:  2011-09-14       Impact factor: 4.599

2.  Molecular cytogenetic characterization of drug-resistant leukemia cell lines by comparative genomic hybridization and fluorescence in situ hybridization.

Authors:  Hajime Shimizu; Takeaki Fukuda; Mohammad Ghazizadeh; Mikio Nagashima; Oichi Kawanami; Toshimitsu Suzuki
Journal:  Jpn J Cancer Res       Date:  2002-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.